Pacylex News has migrated to Newsroom. Click the link below to access the latest articles and press releases.

Pacylex News

Pacylex to Meet with Investors at Bio CEO Conference (BCIC) in New York

CEO Michael Weickert will attend the upcoming BIO CEO & Investor Conference in NYC and will be meeting with investors regarding the company's Series B funding round. The company's lead candidate, zelenirstat, is a first-in-class, orally bioavailable small molecule myristoylation inhibitor, a new mechanism of action for cancer treatment. Zelenirstat is currently being studied in patients who have failed available treatments (refractory or relapsed; r/r). It is in Phase 2 for patients with r/r B-cell non-Hodgkin lymphoma (NHL) and is about to begin Phase 2a in various r/r solid tumors, especially colorectal cancer, and Phase 1/2 in r/r acute myeloid leukemia (AML). Pacylex recently presented Phase 1 results in gastrointestinal cancers at the ASCO-GI conference in San Francisco in January 2024, including a colorectal patient who had been on therapy for more than 340 days and counting with a reduction in tumor volume and blood cancer marker.

February 26, 2024